ASC30 vs Bofanglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ASC30
Developed by Ascletis Pharma
NCT07002905 · Phase 2 · completed
The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2028 · NCT07743463 (registry estimate)
Reported efficacy
Percent change in body weight from Baseline up to Week 13 (Baseline and Week 13): Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo (met)
Result source: NCT07002905
Bofanglutide
Developed by Gan & Lee Pharmaceuticals and partners
NCT06737042 · Phase 2 · completed
This randomized Phase 2 study enrolled 326 adults with obesity or overweight, without type 2 diabetes, at 20 US sites. Bofanglutide (24, 36 or 48 mg every 2 weeks) and placebo were given under double-blind conditions, and tirzepatide 15 mg weekly was an open-label comparator. The primary endpoint was percent change in body weight at 36 weeks. Gan & Lee reported on 12 June 2026 that the study met its primary endpoint: the 48 mg group lost 15.18% of body weight and the tirzepatide group 16.93%, in the per-protocol set. The release gives no placebo figure and no p-value, and no registry results are posted.
Next expected readout: June 2027 · NCT07150975 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ASC30 | Bofanglutide |
|---|---|---|
| Body weight, % change | —Trial running · NCT07743463 | —Not posted · NCT06728124 |
| Weight loss of 5% or more | —Trial running · NCT07743463 | —Not posted · NCT06728124 |
| Weight loss of 10% or more | —Trial running · NCT07743463 | —Not posted · NCT06728124 |
| Waist circumference, change (cm) | —Trial running · NCT07743463 | —Not posted · NCT06728124 |
Body weight, % change
- ASC30
- —Trial running · NCT07743463
- Bofanglutide
- —Not posted · NCT06728124
Weight loss of 5% or more
- ASC30
- —Trial running · NCT07743463
- Bofanglutide
- —Not posted · NCT06728124
Weight loss of 10% or more
- ASC30
- —Trial running · NCT07743463
- Bofanglutide
- —Not posted · NCT06728124
Waist circumference, change (cm)
- ASC30
- —Trial running · NCT07743463
- Bofanglutide
- —Not posted · NCT06728124
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Bofanglutide: no structured comparison results are available for Obesity.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ASC30
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · Bofanglutide's landscape